Interview

FDA Focus: What Mayer Brown's Practice Chair Is Watching

Law360 (August 21, 2018, 3:01 PM EDT) -- Christopher Mikson, newly christened leader of the U.S. Food and Drug Administration practice at Mayer Brown LLP, tells Law360 he's watching for a "dramatic increase" in biosimilar applications, a crackdown on stem cell treatments and congressional action on brand-name drugmakers' anti-generic maneuvers.

Christopher Mikson Mikson, who began leading the practice this year, is based in Washington, D.C., and has been at Mayer Brown since 2015. He came to the firm after a year-and-a-half stint at Jones Day and a 13-year run at Akin Gump Strauss Hauer & Feld LLP.

After earning his law degree at Rutgers Law School, Mikson picked up...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS